NCT05137912 - Neoadjuvant Immunotherapy in Advanced NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

December 1, 2022

Conditions

Lung Cancer, Non-small Cell

Interventions

BIOLOGICAL

Immunotherapy

"Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA.~Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy."

Trial Locations (1)

94107

Power Life Sciences, San Francisco